Summary
Pentagamaboronon-0 (PGB-0), a curcumin analog compound, has been synthesized as a candidate of boron-carrier pharmaceutical (BCP) for boron neutron capture therapy (BNCT); however, this compound is poorly soluble in water. To improve its solubility, aqueous formulations of PGB-0 with a monosaccharide, fructose or sorbitol, were successfully synthesized, namely PGB-0-F and PGB-0-So, respectively. The cytotoxicity study showed that PGB-0-F and PGB-0-So exerted low cytotoxicity against MCF-7 and MDA-MB 231 breast cancer cells. The cellular uptake study using inductively coupled plasma optical emission spectrometry (ICP-OES) and DAHMI live-cell imaging indicated that these compounds were accumulated and distributed within the cytoplasm and cell nuclei. The cellular uptake mechanism was also evaluated to clarify the contribution of the glucose transporter, and the results demonstrated that these compounds entered through active transport into MCF-7 cells but through passive diffusion into MDA-MB 231 cells. In conclusion, the sugar formulations of PGB-0 only improved PGB-0 solubility but had no role in its cellular uptake.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386
Holliday DL, Speirs V (2011) Choosing the right cell line for breast cancer research. Breast Cancer Res 13(4):215
Reis-Filho JS, Pusztai L (2011) Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet (London, England) 378(9805):1812–1823
Rahmawati Y, Setyawati Y, Widodo I, Ghozali A, Purnomosari D (2018) Molecular subtypes of Indonesian breast carcinomas - lack of association with patient age and tumor size. Asian Pac J Cancer Prev 19(1):161–166
Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM (2013) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol 31(2):203–209
Baribeau S, Chaudhry P, Parent S, Asselin É (2014) Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines. PLoS One 9(1):e86987
Bhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, Tkaczuk K, Edelman M, Bao T (2014) Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus 3:366
Barth RF (2009) Boron neutron capture therapy at the crossroads: challenges and opportunities. Appl Radiat Isot 67(7–8 Suppl):S3–S6
Hattori Y, Ishimura M, Ohta Y, Takenaka H, Kirihata M (2016) Visualization of boronic acid containing pharmaceuticals in live tumor cells using a fluorescent boronic acid sensor. ACS Sens 1(12):1394–1397
Sardjiman SS, Reksohadiprodjo MS, Hakim L, van der Goot H, Timmerman H (1997) 1,5-Diphenyl-1,4-pentadiene-3-ones and cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship. Eur J Med Chem 32(7):625–630
Da'i M, Jenie UA, Supardjan AM, Meiyanto E, Kawaichi M (2012) The effect of PGV-1, PGV-0 and curcumin on protein involve in G2-M phase of cell cycle and apoptosis on T47D breast cancer cell line. Jurnal ilmu kefarmasian indonesia 10(2):99–110
Hermawan A, Fitriasari A, Junedi S, Ikawati M (2011) PGV-0 and PGV-1 increased apoptosis induction of doxorubicin on MCF-7 breast cancer cells. Pharmacon 12(2):55–59
Meiyanto E, Putri DDP, Susidarti RA, Murwanti R, Sardjiman n FA, Husnaa U, Purnomo H, Kawaichi M (2014) Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. Asian Pac J Cancer Prev 15(1):179–184
Utomo RY, Putri H, Pudjono P, Susidarti RA, Jenie RI, Meiyanto E (2017) Synthesis and cytotoxic activity of 2,5-Bis(4-Boronic acid)Benzylidine Cyclopentanone on Her2 overexpressed-Cancer cells. Indonesian J Pharm 28(2):74–79
Hattori Y, Kusaka S, Mukumoto M, Ishimura M, Ohta Y, Takenaka H, Uehara K, Asano T, Suzuki M, Masunaga S, Ono K, Tanimori S, Kirihata M (2014) Synthesis and in vitro evaluation of thiododecaborated alpha, alpha- cycloalkylamino acids for the treatment of malignant brain tumors by boron neutron capture therapy. Amino Acids 46(12):2715–2720
Shirakawa T, Inoue N, Mukumoto M, Asano T, Kirihata M Monoclonal antibody against boron carriers of BNCT part 2 preparation and characterization of anti p-boronophenylalanine antibody (anti-BPA MAb). In: Advances in neutron capture therapy 2006 Proceedings of 12th international congress on neutron capture therapy, Japan, 2006. p 638
Shirakawa T, Mukumoto M, Asano T, Kirihata M (2006) Monoclonal antibody against boron carriers of BNCT. Part 1. Preparation and characterization of anti mercaptoundecahydrododecaborate antibody (anti-BSH MAb). Advances in neutron capture therapy Proceedings of 12th international congress on neutron capture therapy 39 (13)
Barth RF, Yang W, Al-Madhoun AS, Johnsamuel J, Byun Y, Chandra S, Smith DR, Tjarks W, Eriksson S (2004) Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors. Cancer Res 64(17):6287–6295
da Silva AFF, Seixas RSGR, Silva AMS, Coimbra J, Fernandes AC, Santos JP, Matos A, Rino J, Santos I, Marques F (2014) Synthesis, characterization and biological evaluation of carboranylmethylbenzo[b]acridones as novel agents for boron neutron capture therapy. Org Biomol Chem 12(28):5201–5211
Akan Z, Ozdemir HS, Oto G, Deniz S, Kacar O, Basak AS, Cakir T, Sinav HU, Demir G (2014) Genotoxicity and cytotoxicity of novel 10B carrier ((2R)-4,5,6-dihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)boronic acid. Med Sci Discov 1(4):96–108
Barth RF, Mi P, Yang W (2018) Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond) 38(1):35
Suzuki T, Douard V, Mochizuki K, Goda T, Ferraris RP (2011) Diet-induced epigenetic regulation in vivo of the intestinal fructose transporter Glut5 during development of rat small intestine. Biochem J 435(1):43–53
Watanabe N, Okochi E, Mochizuki M, Sugimura T, Ushijima T (2001) The presence of single nucleotide instability in human breast cancer cell lines. Cancer Res 61(21):7739–7742
Khojah R, Stoutamore R, Di Carlo D (2017) Size-tunable microvortex capture of rare cells. Lab Chip 17(15):2542–2549
Genady AR (2009) Promising carboranylquinazolines for boron neutron capture therapy: synthesis, characterization, and in vitro toxicity evaluation. Eur J Med Chem 44(1):409–416
Szachowicz-Petelska B, Figaszewski Z, Lewandowski W (2001) Mechanisms of transport across cell membranes of complexes contained in antitumour drugs. Int J Pharm 222(2):169–182
Wittig A, Sauerwein WA, Coderre JA (2000) Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiat Res 153(2):173–180
Putra S, Meilani Nurcahya B, Sudarmanto A, Meiyanto E (2008) Curcumin and its analogues as selective estrogen receptor modulators (SERMS}: the study of docking method on estrogen alpha receptors. Pharmacon 9(1):6–13
Wilson FA, Treanor LL (1975) Characterization of the passive and active transport mechanisms for bile acid uptake into rat isolated intestinal epithelial cells. Biochim Biophys Acta 406(2):280–293
Barth RF, Vicente MG, Harling OK, Kiger WS 3rd, Riley KJ, Binns PJ, Wagner FM, Suzuki M, Aihara T, Kato I, Kawabata S (2012) Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol (London, England) 7:146
Fuwa N, Suzuki M, Sakurai Y, Nagata K, Kinashi Y, Masunaga S, Maruhashi A, Imahori Y, Kodaira T, Tachibana H, Nakamura T, Ono K (2008) Treatment results of boron neutron capture therapy using intra-arterial administration of boron compounds for recurrent head and neck cancer. Br J Radiol 81(969):749–752
Kankaanranta L, Saarilahti K, Makitie A, Valimaki P, Tenhunen M, Joensuu H (2011) Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as primary treatment of large head and neck cancer with intracranial involvement. Radiother Oncol 99(1):98–99
Yong Z, Song Z, Zhou Y, Liu T, Zhang Z, Zhao Y, Chen Y, Jin C, Chen X, Lu J, Han R, Li P, Sun X, Wang G, Shi G, Zhu S (2016) Boron neutron capture therapy for malignant melanoma: first clinical case report in China. Chin J Cancer Res 28(6):634–640
Makino E, Sasaoka S, Aihara T, Sakurai Y, Maruhashi A, Ono K, Fujimoto W, Hiratsuka J (2012) The first clinical trial of boron neutron captures therapy using 10B-para-boronophenylalanine for treating extra-mammary Paget’s disease. Eur J Cancer 48:S244–S245
Funding
The authors acknowledge the financial support from the Ministry of Research and technology through World Class Professor Program 2018, Contract No. 123.9/D2.3/KP/2018.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All the authors declare that there is no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hermawan, A., Susidarti, R.A., Ramadani, R.D. et al. Cellular uptake evaluation of pentagamaboronon-0 (PGB-0) for boron neutron capture therapy (BNCT) against breast cancer cells. Invest New Drugs 37, 1292–1299 (2019). https://doi.org/10.1007/s10637-019-00765-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-019-00765-9